Teclistamab, Daratumumab, and Lenalidomide Demonstrates Encouraging Safety in RRMM
December 10th 2022Results from the phase 1b MajesTEC-2 trial showed that teclistamab plus daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.
Read More
Obintutuzumab Given Prior to Fixed-Duration Glofitamab Shows Durable Responses in R/R MCL
December 10th 2022Pretreatment with Obinutuzumab aids fixed-duration regimen of glofitamab in high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.
Read More
Camizestrant Bests Fulvestrant in HER2̶̶-Negative Advanced Breast Cancer Subset
December 8th 2022Treatment with various camizestrant monotherapy doses lead to survival benefit compared with fulvestrant in a post-menopausal patient population diagnosed with estrogen receptor–positive, HER2-negative advanced breast cancer.
Read More
Continuing CDK4/6 Does Not Improve PFS in ER+/HER2- Breast Cancer
December 8th 2022The combination of palbociclib and fulvestrant beyond progression on prior CDK4/6 inhibitor did not show significant improvements in progression-free survival compared with fulvestrant alone in ER-positive/HER2-negative breast cancer.
Read More
Clinical Benefit for ARV-471 Continues to Impress in Expansion Cohort in ER+/HER2– Breast Cancer
December 8th 2022Results from the VERITAC trial presented at the 2022 San Antonio Breast Cancer Symposium showed that ARV-471 monotherapy may be active in ER-positive/HER2-negative locally advanced/metastatic breast cancer.
Read More
Trastuzumab Deruxtecan Maintains Survival Advantage Over T-DM1 After Years HER2+ mBC
December 7th 2022Trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in overall versus TDM-1 as well as a continued PFS benefit, according to Sara A. Hurvitz, MD.
Read More
Percentage of Actionable Mutations in Prostate Cancer Underscores Importance of Testing
November 12th 2022During a presentation, Emmanuel S. Antonarakis, MD explained that homologous repair mutations and mismatch mutations in prostate cancer have therapeutic implications in the context of PARP inhibitors and PD-1 inhibitors.
Read More